1 unchanged sentence
Market Information
−Removed: Our common stock began trading on Nasdaq under the symbol “BBIO” on June 27, 2019.
+Added: Our common stock began trading on The Nasdaq Global Select Market, or the Nasdaq, under the symbol “BBIO” on June 27, 2019.
Prior to that date, there was no public trading market for shares of our common stock.
6 unchanged sentences
Stock Performance Graph
−Removed: The graph set forth below compares the cumulative total stockholder return on our common stock for the period commencing on June 27, 2019 and ending on December 31, 2019, with the cumulative total return of the Nasdaq Composite Index and the Nasdaq Biotechnology Index over the same period.
−Removed: This graph assumes the investment of $100.00 on June 27, 2019 in each of our common stock at the IPO price, the Nasdaq Composite Index, and the Nasdaq Biotechnology Index, and assumes the reinvestment of dividends.
+Added: The graph set forth below compares the cumulative total stockholder return on our common stock for the period commencing on June 27, 2019, the date our common stock began trading on the Nasdaq, and ending on December 31, 2020, with the cumulative total return of the Nasdaq Composite Index and the Nasdaq Biotechnology Index over the same period.
+Added: This graph assumes the investment of $100.00 on June 27, 2019 in each share of our common stock at the initial public offering price of $17.00, the Nasdaq Composite Index, and the Nasdaq Biotechnology Index, and assumes the reinvestment of dividends.
The comparisons shown in the graph below are based upon historical data.
1 unchanged sentence
Information used in the graph was obtained from sources believed to be reliable including Nasdaq, Bloomberg and Reuters, but we are not responsible for any errors or omissions in such information.
−Removed: Notwithstanding anything to the contrary set forth in any of our previous or future filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, that might incorporate this Annual Report on Form 10‑K or future filings made by us under those statutes, this Stock Performance Graph section is not “soliciting material,” shall not be deemed filed with the SEC and shall not be deemed incorporated by reference into any of those prior filings or into any future filings made by us under those statutes.
+Added: Notwithstanding anything to the contrary set forth in any of our previous or future filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, that might incorporate this Annual Report on Form 10‑K or future filings made by us under those statutes, this Stock Performance Graph section is not “soliciting material,” shall not be deemed filed with the U.S.
+Added: Securities and Exchange Commission and shall not be deemed incorporated by reference into any of those prior filings or into any future filings made by us under those statutes.
COMPARISON OF CUMULATIVE TOTAL RETURN*
−Removed: Among BridgeBio Pharma, Inc.
−Removed: the Nasdaq Composite Index, and Nasdaq Biotechnology Index
−Removed: $100 invested on June 27, 2019 in stock or index, including reinvestment of dividends.
+Added: Among BridgeBio Pharma, Inc., the Nasdaq Composite Index and the Nasdaq Biotechnology Index
+Added: $100 invested on June 27, 2019 in shares of our common stock or index, including reinvestment of dividends.
Sales of Unregistered Securities
−Removed: During the year ended December 31, 2019, we did not issue or sell any unregistered securities.
+Added: During the year ended December 31, 2020, we did not issue or sell any unregistered securities other than as disclosed in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020.
Issuer Purchases of Equity Securities
−Removed: We have not made any purchases of our own equity securities for the year ended December 31, 2019.
−Removed: SELECTE D CONSOLIDATED FINANCIAL DATA
−Removed: The selected consolidated financial data below should be read in conjunction with Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Part II, Item 8, “Financial Statements and Supplementary Data,” in this Annual Report on Form 10‑K.
−Removed: The historical results are not necessarily indicative of the results to be expected in any future period.
−Removed: Year Ended December 31,
−Removed: (in thousands, except share and per share data)
−Removed: Consolidated Statements of Operations Data:
−Removed: License revenue
−Removed: Operating expenses:
−Removed: Cost of license revenue
−Removed: Research and development
−Removed: General and administrative
−Removed: Total operating expenses
−Removed: Loss from operations
−Removed: Other income (expense), net:
−Removed: Interest income
−Removed: Interest expense
−Removed: Gain on deconsolidation of PellePharm
−Removed: Loss from ML Bio asset acquisition
−Removed: Share in net loss of equity method investments
−Removed: Other expense
−Removed: Total other income (expense), net
−Removed: Net loss attributable to redeemable convertible
−Removed: noncontrolling interests and noncontrolling
−Removed: Net loss attributable to common stockholders
−Removed: Net loss per share, basic and diluted
−Removed: Weighted-average shares used in computing net loss
−Removed: per share, basic and diluted
−Removed: As of December 31,
−Removed: (in thousands)
−Removed: Consolidated Balance Sheet Data:
−Removed: Cash and cash equivalents and marketable securities
−Removed: Working capital (1)
−Removed: Term loans, noncurrent
−Removed: Other liabilities
−Removed: Redeemable convertible noncontrolling interests
−Removed: Additional paid-in capital
−Removed: Accumulated other comprehensive income
−Removed: Accumulated deficit
−Removed: Noncontrolling interests
−Removed: Total stockholders' equity
−Removed: We define working capital as current assets less current liabilities.
−Removed: Refer to our consolidated balance sheets and notes to our financial statements for further details regarding our current assets and current liabilities.
+Added: We used approximately $75.0 million of the net proceeds from the offering of our 2.50% Convertible Senior Notes due 2027, or 2027 Notes, to repurchase 2,414,681 shares of our common stock concurrently with the closing of the offering from certain of the initial purchasers of the 2027 Notes in privately negotiated transactions, or the Repurchases.
+Added: The agreed to purchase price per share of common stock in the Repurchases is equal to $31.06, which was the last reported sale price per share of our common stock on the Nasdaq on March 4, 2020.
+Added: SELECTED CONSOLIDATED FINANCIAL DATA
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.